{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-055899","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.394210+00:00","generated_at":"2026-06-27T03:48:42.360081+00:00","sec_items":["2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Gemini cuts workforce ~80%, initiates strategic review; CEO departs","bullets":["Workforce reduction of 24 employees (approx. 80%) by end of Q2 2022; restructuring charge $1.6-1.9M in Q1 2022.","CEO Jason Meyenburg departs; Executive Chair Georges Gemayel appointed interim President and CEO.","Company initiates strategic alternatives review to maximize shareholder value; no timetable set.","Remaining employees to focus on GEM307 IND-enabling tasks.","Separation agreement includes 12 months base salary, pro-rata bonus, COBRA, and continued equity vesting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-055899","json":"https://secwatch.observer/filing/0001193125-22-055899.json","markdown":"https://secwatch.observer/filing/0001193125-22-055899.md","text":"https://secwatch.observer/filing/0001193125-22-055899.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000119312522055899/0001193125-22-055899-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000119312522055899/d29362d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:48:42.360081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65df71989f","claim":"Jason Meyenburg resigned as President and Chief Executive Officer at Disc Medicine, Inc..","evidence_excerpt":"Mr. Meyenburg’s last date of employment with the Company as its President and Chief Executive Officer is February 28, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312522055899/0001193125-22-055899-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"b9a691e852","claim":"Georges Gemayel was appointed as Interim President and Chief Executive Officer at Disc Medicine, Inc..","evidence_excerpt":"the Board appointed Dr. Georges Gemayel, the Company’s current Executive Chair, to serve as Interim President and Chief Executive Officer, effective as of February 28, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312522055899/0001193125-22-055899-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}